Angiotensin II receptor blockade: a novel strategy to prevent immunosuppressant-associated cancer progression.
Maluccio
M
M
Division of Nephrology, Department of Transplantation and Extracorporeal Therapy, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, New York, USA.
Sharma
V
V
Lagman
M
M
Konijn
G
G
Suthanthiran
M
M
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000818:Animals; D002292:Carcinoma, Renal Cell / Q000517:prevention & control* / Q000556:secondary; D016572:Cyclosporine / Q000009:adverse effects*; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D019808:Losartan / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000517:prevention & control* / Q000556:secondary; D051379:Mice; D008807:Mice, Inbred BALB C; D008815:Mice, Inbred Strains; D016513:Mice, SCID
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D019808:Losartan